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Abstract
Yersinia pestis is a Gram negative zoonotic pathogen responsible for causing bubonic and pneumonic plague in humans.
The pathogen uses a type III secretion system (T3SS) to deliver virulence factors directly from bacterium into host
mammalian cells. The system contains a single ATPase, YscN, necessary for delivery of virulence factors. In this work, we
show that deletion of the catalytic domain of the yscN gene in Y. pestis CO92 attenuated the strain over three million-fold in
the Swiss-Webster mouse model of bubonic plague. The result validates the YscN protein as a therapeutic target for plague.
The catalytic domain of the YscN protein was made using recombinant methods and its ATPase activity was characterized in
vitro. To identify candidate therapeutics, we tested computationally selected small molecules for inhibition of YscN ATPase
activity. The best inhibitors had measured IC50 values below 20 mMi na nin vitro ATPase assay and were also found to inhibit
the homologous BsaS protein from Burkholderia mallei animal-like T3SS at similar concentrations. Moreover, the compounds
fully inhibited YopE secretion by attenuated Y. pestis in a bacterial cell culture and mammalian cells at mM concentrations.
The data demonstrate the feasibility of targeting and inhibiting a critical protein transport ATPase of a bacterial virulence
system. It is likely the same strategy could be applied to many other common human pathogens using type III secretion
system, including enteropathogenic E. coli, Shigella flexneri, Salmonella typhimurium, and Burkholderia mallei/pseudomallei
species.
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Introduction
The Gram negative bacterium, Yersinia pestis, is a zoonotic
pathogen responsible for epidemics of human plague [1]. The
pathogen can be spread by flea bites, causing bubonic plague, or
through aerosol exposure, causing pneumonic plague. There is no
approved vaccine licensed for human use in the United States and
to be effective, antibiotics have to be given within 24-hr post-
exposure to the aerosolized form of pathogen. In view of the
potential for natural and artificial resistance to the current
antibiotics, alternative forms of treatments, preferably compatible
with the existing therapeutics, are of interest to the medical
community. Recent interests of researchers are focused on many
aspects of the infection process, including blocking transcriptional
activation, inhibiting function of proteins secreted by bacteria
during infection, or disabling the full virulence system by
interference with its assembly and function. In many Gram
negative bacteria, including Y. pestis, the type III secretion system
(T3SS) is the preferred target for novel therapeutics development
using the described strategies [2,3,4,5,6,7,8,9]. The system has
been studied extensively and there is a direct evidence for its
essential role in virulence in Y. pestis and other pathogens [10,11].
The system is encoded on a plasmid, pCD1 in Y. pestis, and is
conserved across species. Structurally, the organization is very
similar to the bacterial flagellar system and many proteins are
direct homologues of the flagellar system [12]. Yersinia pestis
assembles the outside shell, the injectisome, composed of Ysc
proteins (Yersinia secretion chaperone) to deliver Yops( Yersinia outer
proteins) directly from the bacteria into the mammalian cell
(review in [13]). The delivery is cell-contact-dependent and one of
the primary host targets are macrophages. The secreted proteins,
which include YopH, a phosphatase, and YopE, a potent activator
of human Rho GTPases, disrupt the cellular signaling network
enabling Yersinia to survive intracellular and to potentially be
spread through macrophages [14,15]. The mechanism of Yops
delivery is known in general but the fine details are not clear. In
the bacterial cytoplasm, many Yop effectors (YopE, YopH, YopB,
YopD, YopO/YpkA, and YopT) are made in complex with Syc
(specific Yersinia chaperone) proteins to prevent degradation and
keep them in a partially unfolded state. The partial unfolding,
confirmed by structural data, is presumed to be necessary for
transport through the pore as the measured pore diameter is not
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removal of chaperones is facilitated by a single ATPase and requires
ATPhydrolysis[18].Intheplant-likeT3SSs,thehomologousHrcN
ATPase forms a double hexameric head-to-head assembly located
in the center of the entrance to the translocation pore [19]. In the
animal-like T3SSs, which include Y. pestis system, the ATPase is
most likely attached to the side of the translocation pore [20]. It is
hypothesized that the oligomeric, most likely hexameric, form of the
ATPase in the animal-like T3SS is necessary for its biological
activity [21]. The energy source for the transport of the proteins
through the pore is not known. In the flagellar system, a proton
gradient has been proposed as the potential energy source [22], but
this hypothesis is still controversial.
The structural and functional conservation of the T3SSs across
many pathogens has made it an attractive target for novel
antibacterial therapeutics development with broad spectrum
activity. In the enteropathogenic Escherichia coli, EscN, a homolog
of YscN, is essential for virulence in the animal mode of infection,
and deletion of the gene or a mutation in the catalytic site of the
protein abolishes the delivery process of virulence factors [23]. In
Y. enterocolitica, deletion of the yscN gene abolishes secretion of all
Yop effectors in a bacterial cell culture model [24]. Deletions in
the animal-like T3SS in Burkholderia mallei, a zoonotic pathogen
responsible for glanders and a CDC select agent [25,26],
decreased the virulence of the pathogen at least two orders of
magnitude in an animal model [25]. Because B. mallei also has a
type VI secretion system (T6SS) essential for virulence [27], the
data may reflect partial attenuation.
Current strategies for T3SS inhibition strategies do not
specifically target the T3SS ATPases [2,3,4,5,6,7,8,9] due to
concerns of a future therapeutic cross-reacting with human
enzymes. However, the bacterial enzymes have less than 25%
identity to human ATPases and the active sites show significant
differences between bacterial and human enzymes. In this work,
effort was focused on the YscN ATPase as the target for
interference with the function of the T3SS in Y. pestis.T h eyscN
gene was shown to be essential for virulence of Y. pestis in a
mouse model of bubonic plague as deletion of the region coding
for the catalytic domain of the YscN ATPase totally attenuated
the pathogen. Therefore, the catalytic domain of the recombi-
nant enzyme was purified under native conditions as a fusion
with a maltose-binding protein (MBP) and characterized
biochemically. The protein had ATPase activity which required
Mg
+2 for its activity. To help design potential small-molecule
inhibitors of the enzyme, a database of commercially available
drug-like molecules was computationally screened against the
active site. The best candidates from a small test set were able to
fully inhibit the YscN ATPase activity in an in vitro assay at
micromolar concentrations. The same compounds also inhibit
the homologous B. mallei BsaS ATPase activity in an in vitro assay
at similar concentrations. In addition, the small molecules
prevent secretion of the YopE effector by attenuated Y. pestis
into the bacterial medium and mammalian cells at micromolar
concentrations. The current work shows the feasibility of
targeting T3SS ATPases towards the future development of
novel, broad-spectrum bacterial therapeutics.
Results
The yscN gene is essential for plague virulence
The high functional conservation of T3SS in bacteria and the
presence of a single ATPase per virulence system suggest a critical
role for the ATPase protein in the function of T3SS. In other
bacteria, deletion of the orthologous ATPase abolishes the
secretion of virulence factors thereby decreasing the virulence
of the pathogen [10,28]. The deletion of the Y. pestis CO92 YscN
ATPase would be expected to at least decrease the secretion of
virulence factors, including Yops and LcrV, and possibly
attenuate the virulence of Y. pestis CO92. Indeed, the in-frame
deletion of the yscN gene (Fig. 1) caused total attenuation of the
pathogen. The LD50 for the s.c. route of delivery was greater than
3.2610
6 CFU in the Swiss-Webster model of plague (Table 1).
The deletion did not affect the growth rate of the mutant in vitro
(Fig. 2) which confirms that the deletion does not affect overall
metabolism of the bacteria under in vitro conditions. The results
confirm a very well known fact that the TTSS is essential for
virulence but not for survival of bacteria outside the host [29].
The LD50 for the s.c. route of delivery of the DyscN Y. pestis CO92
mutant was greater than 3.2610
6 CFU in the Swiss-Webster
model of plague (Table 1), which is in a strong contrast to the well
established value of LD50 of 1–2 CFU for the wild-type Y. pestis
CO92 bubonic plague infection model in Swiss-Webster mice
[30]. Attempts to calculate a complete LD50 were not successful
as higher doses could not be used due to the physical limitation of
the delivery method. None of the animals died within the 21 days
after inoculation and no signs of discomfort (ruffled fur, excessive
grooming, and signs of morbidity) were observed during the
course of the experiment. Due to the well-established lethality of
Y. pestis and to reduce unnecessary animal use, a single dose of
180 CFU of the wild-type pathogen was used as a positive
control. None of the animals from the control group survived
beyond the 21 days post-inoculation observation period. In
contrast, all the animals inoculated with up to 3.2610
6 CFU
survived for 21 days post-inoculation. These current data prove
that the yscN gene is essential for Y. pestis virulence and the
observed attenuation is not due to the interference with the
overall metabolism of Y. pestis.
Fusion of YscN catalytic domain with maltose binding
protein retains ATPase activity despite oligomerization
Expression and purification of the ATPase-active form of the
YscN protein proved to be a challenging protein engineering
effort. The YscN protein in Y. pestis is predicted to be an Mg
2+-
dependent ATPase. The full length protein expressed very poorly
in E. coli and had to be fused to a permanent membrane anchor to
increase yield. This version was not suitable for characterization as
the detergent interfered with ATPase activity of the protein.
Instead, an N-terminal fusion with MBP was chosen to avoid the
presence of detergents. This strategy is commonly used for
studying difficult-to-express proteins and MBP solubility tag has
been used to express many functional ATPases [31,32,33]. The
MBP fusion of wild-type YscN protein was stable in E. coli but
tended to aggregate and the yield was very low. The yield was not
Figure 1. yscN gene deletion in Y.pestis CO92. The yscN gene
fragment (black box) was deleted in the pCD1 plasmid as described
under Materials and Methods. The approximate position of ATPase
domain is marked with the bar on the top of the box. Numbers below
the box correspond to approximate positions in the amino acid
sequence marking the boundaries of the deleted region.
doi:10.1371/journal.pone.0019716.g001
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and all of the three Cys residues were replaced by Ser to prevent
aggregation due to non-native intermolecular disulfide bridge
formation. However, shortening of the expression construct to the
catalytic domain region amino acid residues 94–419, removal of
the C-terminal 20 residues and a replacement of the single Cys
residue with Ser improved the yield dramatically and retained the
ATPase activity of the recombinant protein. The MBP affinity tag
was not removed as cleavage with proteases necessitated inclusion
of detergents to prevent aggregation. The optimized catalytic
domain fragment, residues 94–419, fused to the MBP anchor, was
used throughout all the experiments. The fragment will be referred
to as ‘optimized YscN catalytic domain’ in the current work.
The optimized YscN catalytic domain purified as an oligomeric
species. The major peak eluted at 118 mL on a HiLoad Superdex
200 26/60 gel filtration column, which corresponded to a
hydrodynamic radius of a hexamer or a higher-order oligomer.
The smaller peaks constituted less than 10% of the main peak area
and did not contain the optimized YscN catalytic domain protein
as examined by SDS-PAGE.
The observed aggregation could be a result of a severe
misfolding of the YscN protein or reflect a non-specific
oligomerization due to the hydrophobic properties of the YscN
protein. The severely misfolded protein would exhibit a minimal
ATPase activity as compared to other reported homologous
proteins. To investigate the issue in detail, we examined the
kinetics of the ATP hydrolysis. The initial velocity of phosphate
release from ATP increased with the initial concentration of
substrate up to about 4 mM (Fig. 3A). After that, the initial rate
decreased which is observed commonly in kinetics measurements
at over-saturating enzyme concentrations. The kinetics up to
[ATP]=4 mM showed a positive cooperativity with a Hill’s
coefficient of 1.3160.28 (Fig. 3B), similar to the data observed for
the homologous EscN enzyme [34]. Steady-state analysis of the
kinetics determined apparent Vmax and Km values of
10.5260.51 mmole Pi/min/mg of enzyme and 0.3660.06 mM,
respectively. Corrections for the cooperativity did not improve fit
quality and were not included in the final apparent Km and Vmax
calculations. The specific ATPase activity of the YscN catalytic
domain (Fig. 3 A) was about an order of magnitude higher than
reported for the homologous EscN protein [34] but about two
orders of magnitude lower than reported for the Y. enterocolitica
YscN enzyme [35]. The optimized catalytic domain of YscN has
measured ATPase activity within the fairly broad reported range
of specific activities of various other ATPases. In summary, the
data preclude a gross misfolding of the protein and show positive
cooperativity by the enzyme during ATP hydrolysis.
Inhibition of YscN optimized catalytic domain by small
molecules
To help us search for the inhibitors of the Y. pestis T3SS
ATPase, we performed computational screening of a virtual 3D
database [36] of drug-like molecules against a comparative
protein model of the active site of YscN. The first phase of the
search identified about 20,000 compounds, while the second
phase led to the selection and purchase of 50 compounds with
LigScore2 (Accelrys) values.=6.8. The hydrophobic nature of
the compounds prevented characterization of YscN inhibition at
values greater than 100 mM ligand concentrations. Due to the
solubility problems, only 37 of the purchased compounds
(Appendix S1) were used in biological assays. Attempts to use
alternative methods (high/low pH, high temperature) for the rest
of the compounds were not successful as the compounds
precipitated from the reaction mixtures during activity assays.
The first screen of the enzyme using the soluble compounds
identified several compounds capable of fully inhibiting the
ATPase activity at 100 mM concentration (Fig. 4). A detailed
analysis of the inhibition determined that several compounds
could inhibit 50% of the ATPase activity below 40 mM
concentration (Table 2). The best ones, compounds with ID
numbers 7146 and 1504, were effective below 20 mM concen-
tration. The data were not affected by the amount of DMSO
used in the assay and the results were repeated many times in
independent measurements, demonstrating stability of the
compounds in the solvent and reliability of the assays. The only
exception was compound with ID number 4640 which changed
its inhibitory properties after prolonged storage in DMSO at
room temperature. Compound 3624 was not used in the ATPase
inhibition assays due to the interference of intrinsic fluorescence
with the Adapta (Invitrogen) assay.
Figure 2. Deletion of the yscN gene in Y. pestis CO92 strain does
not affect the growth of bacteria. Fresh dilutions of the wild type
and DyscN strains of bacteria were grown at 28uC as described under
Materials and Methods. A graph for one of the representative
experiments is presented.
doi:10.1371/journal.pone.0019716.g002
Table 1. The DyscN gene deletion in Y. pestis CO92 creates a
fully attenuated DyscN CO92 strain in a mouse model of
bubonic plague.
Dose Survival after 21 days
CFU alive/total
0 10/10
32 10/10
322 10/10
3220 10/10
32200 10/10
322000 10/10
3220000 10/10
32000000 10/10
Control 0/10*
Groups of 10 Swiss-Webster female mice were inoculated s.c. with the deletion
mutant and observed for 21 days as described under Materials and Methods.
Data are statistically valid (p,0.05). For control experiments, the animals were
challenged with 180 CFU of wt Y. pestis CO92 strain as described under
Materials and Methods.
doi:10.1371/journal.pone.0019716.t001
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concentration. (B) The hydrolysis of ATP by the enzyme shows a positive cooperativity up to 4 mM ATP concentration. The kinetics of hydrolysis was
measured by following phosphate release in 10 mM Tris, pH=7.6, 150 mM NaCl, and 1 mM Mg
+2 at 37uC as described under Materials and Methods.
Total protein concentration was 9.6 mg. Error bars correspond to standard deviation of triplicate measurements.
doi:10.1371/journal.pone.0019716.g003
Figure 4. Small-molecule inhibitors are capable of fully blocking the optimized catalytic domain ATPase activity. The small molecules
derived from computational screen of ZINC database were incubated with the enzyme at 37uC and ATP hydrolysis was determined by measuring
ADP release as described under Materials and Methods. Inhibitor concentrations were 100 mM for all reactions. The numbers on the X axis correspond
to in-house IDs for individual compounds. Error bars correspond to standard deviation of triplicate measurements.
doi:10.1371/journal.pone.0019716.g004
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inhibit homologous B. mallei BsaS ATPase
The B. mallei BsaS ATPase shares over 40% sequence identity
with Y. pestis YscN ATPase and the active site is almost identical in
both pathogens based on homology modeling. It has been shown
for many pathogens using the same type of virulence factors
delivery systems that compounds effective against one species are
effective against other species [37]. Accordingly, we hypothesized
that the best molecules effective against Y. pestis T3SS ATPase
would have an effect on the homologous B. mallei T3SS near-full-
length BsaS ATPase. Indeed, the hypothesis was confirmed
experimentally (Table 3). The small differences in IC50 values
likely reflected small changes in the active site of the proteins as
both ATPases were purified under native conditions using the
same strategy. The results show feasibility of developing broad-
spectrum inhibitors targeting T3SS ATPases.
The comparative protein model of YscN used in the in silico
screening effort and models of the best inhibitors docked onto the
protein surface are illustrated in Fig. 5. The compounds shown are
ID 7812, 7146, and 7086. The docked conformational poses are
overall similar among the molecules, yet their chemical compo-
sition and the details of their interaction with YscN are different.
The binding pocket flanked by YscN residues Y325 and T398 is
occupied by ring structures of the small molecules and the binding
interactions reflect potential p-p stacking with the tyrosine ring.
This tyrosine-based pocket is the binding site for the adenine
moiety of ADP as observed in various crystallographic structures
of ATPases and ATP synthases, including the structure used to
build our comparative model of YscN. The compound 7146
extended well into the YscN pocket by placing chemical groups
that exhibit strong polarity, and thus may help to explain the more
favorable IC50 for this molecule. The cavity at YscN residues
R178 and E179 is the location of binding the phosphate groups of
ADP. The compound 7812 extends into this cavity and provides
surface complementarity through multiple ring structures.
Small-molecule ATPase inhibitors are effective in
blocking YopE secretion by Y. pestis in a bacterial cell
culture
The small-molecule compounds shown to be effective against
YscN and BsaS ATPase were tested in a cell culture assay for
inhibition of the secretion of virulence factors. Many of the
compounds inhibiting YscN ATPase activity (Fig. 4) also inhibited
the secretion of YopE by the attenuated Y. pestis (Fig. 6). The
compounds with ID numbers 7146 and 1504 had the lowest IC50
(Table 2) but were poor inhibitors of the YopE secretion (Fig. 6).
The compounds with ID numbers 7812, 7086, and 7832 were also
good inhibitors of YopE secretion (at least 50% inhibition at
50 mM or lower concentration, Fig. 6) and had the IC50 estimates
between 30 and 70 mM (Table 2).However, the compound 9652
was poor in the secretion inhibition assay (30% at 100 mM
concentration, Fig. 6). The three compounds: 7812, 7832 and
7086, showed a good correlation between inhibition of YopE
secretion and the ATPase activity and were selected for further
studies. There were several compounds which showed excellent
YopE secretion inhibition at 100 mM concentration despite
marginal performance in the ATPase inhibition assay: compound
IDs 4642, 6548, 7234, 4918, 598, 7454, 4984, 7509, 7882, 3716,
5050, 5238, and 3284. The compound 3624 showed excellent
performance in the YopE secretion assay but was unsuitable for
the ATPase inhibition assays. The compounds with IDs 4214 and
9820 showed lack of inhibition in both assays. The differences may
be due to many factors discussed below.
The overall correlation between the activity and secretion assays
was very poor (Student t-test, paired data: p,0.006). The reason
for the discrepancy between the two assays is not clear but may
involve ability of the compounds to enter bacterial cells and
interact with the YscN ATPase, metabolism inside the bacteria,
efflux from the pathogen, and interaction with other bacterial
proteins, including those important for T3SS function and
assembly. The last option may be an explanation for the
compound 4918, among others.
The difference cannot be explained by misfolding of the protein
as both BsaS and YscN ATPases, with only 40% identity, were
inhibited by the same compounds with a similar potency (Table 3).
Possible explanations may include binding outside the catalytic
pocket of YscN and affecting assembly of biologically important
complexes or targeting sterically similar sites in other bacterial
proteins important for regulating the effector secretion
[38,39,40,41].
To help us find a correlation between the chemical activity and
blockage of bacterial secretion, we performed chemical similarity
analysis on the 29 compounds that had YopE secretion inhibition,
EC50, better than 100 mM. The largest cluster of active
compounds all contained a thiophene group. A smaller cluster
contained molecules in which a sulfonyl group bridges an aniline
and phenyl ring. The most noticeable feature amongst the top hits
for EC50 and enzymatic activity (IC50) was the presence of a 6-
member ring fused to a 5-member ring, which is topologically
similar to the purine/adenine moiety found in ADP and ATP. The
best inhibitors may then represent chemical mimics of the
bacterial ATPase substrate.
Table 2. IC50 values
a for inhibition of ATP hydrolysis by YscN
optimized catalytic domain for selected small molecules.
Compound ID IC50, mM
7812 41 b
7146 16.561.5
1504 18.264.9
7086 32 a
9652 50 a
7832 70 a
The ATPase inhibition was measured by following ADP release at 37uCa s
described under Materials and Methods.
aThe value was determined from the best fit as the concentration at which 50%
inhibition of ATPase activity was observed.
doi:10.1371/journal.pone.0019716.t002
Table 3. Top inhibitors of YscN ATPase cross- inhibit ATP
hydrolysis by near-full-length BsaS ATPase.
a
Compound IC50
In-house ID mM
7812 23615
7146 7.460.9
1504 28.467.4
aThe ATPase inhibition was measured by following ADP release at 37uCa s
described under Materials and Methods. The values were determined as the
concentrations at which 50% inhibition of ATPase activity was observed.
doi:10.1371/journal.pone.0019716.t003
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19716Figure 5. Structural model of YscN ATPase with compounds docked into the active site. (A) Protein fold of the YscN model (colored
yellow) built by comparative modeling methods and illustrated with the docked compound ID number 7812 (depicted by atomic spheres). (B)
Molecular surface of the YscN model showing the active-site region (colored gold) bound by compound ID 7812 in its conformational pose (stick
representation, where in general the color cyan are carbon atoms, nitrogen atoms are blue, oxygen are red, and sulfur are yellow). (C) Modeled YscN
complex with compound ID 7146. (D) Modeled YscN complex with compound ID 7086.
doi:10.1371/journal.pone.0019716.g005
Figure 6. Inhibition of YopE secretion by selected small molecules. The secretion of YopE was measured in the supernatants of bacterial cell
culture by ELISA using anti-YopE antibody as described under Materials and Methods. The data were collected 1 hr post-induction with EGTA.
Inhibitor concentrations were 100 mM. Positive and negative controls correspond to the results obtained for co-solvent (DMSO) without and with
EGTA, respectively. Error bars correspond to standard deviation of five measurements.
doi:10.1371/journal.pone.0019716.g006
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and Fig. 6) could also be caused by the inhibitors’ influence on the
general bacterial growth. We selected compounds 7812, 7832 and
7086 as the most promising compounds based on their combined
scores from YopE secretion and ATPase inhibition assays and
further analysis discussed below. Bacterial growth in the presence
of selected inhibitors 7832 and 7812, showed that none of them
had a significant effect on the growth rate of Y. pestis in a bacterial
medium (Fig. 7) except for the compound 7086 which had a small
bacteriostatic effect. The results confirm that the selected small
molecules, except maybe for the compound 7086, do not affect the
general metabolism of Y. pestis and exclude slower growth rate of
bacteria in the presence of inhibitors as the cause of YopE
secretion inhibition.
The bioavailability of the compounds was not tested directly in
the current work. Indirectly, we performed a second screen of YopE
secretion inhibition at 10 mM inhibitorconcentration forthe best 21
compounds tested at 100 mM (Fig. 6).Only threecompounds: 7812,
7832, and 7086, would inhibit YopE secretion at 95% or higher
levels (Table 4). The compounds were only moderate (45–60%)
inhibitors in the ATPase activity assay (Fig. 4). The compounds
7812 and 7832 also showed minimal bacterial growth inhibition at
100 mM concentration (Fig. 7) but the compound 7086 had some
bacteriostatic effect. The observed inhibition of YopE secretion is
most likely related to the inhibition of T3SS ATPase activity
(compounds 7812, and 7832) except for the compound 7086.
Compound 7086 inhibits the ATPase activity but it also has a slight
bacteriostatic effect. In this case, the inhibition of secretion may be
due to some interference with the bacterial growth.
The next step in compound screening was determination of
cytotoxicity on mammalian cells alone by the top overall scoring
compounds (Table 4). At 100 mM concentration, the compounds
7812, 7832 and 7086 showed minimal general cell toxicity against
HeLa cells (Table 5) while inhibiting at least 80% the YopE
secretion in a bacterial cell culture (Fig. 6), making them potential
therapeutic candidates. However, compound 7086 exhibited a
noticeable toxic effect and would have to be modified as a
potential therapeutic candidate. Compound 3624 showed about
20% cell toxicity at 100 mM concentration.
The last step in the screening process was determination of the
ability to block the toxic effects to mammalian cells by the
molecules. Delivery of effectors by Y. pestis causes morphological
changes in the mammalian cells due to the actin depolimerization
mainly by YopE [42]. The infected cells change their normal
morphology and become rounded up due to the destruction of
mammalian cytoskeleton. We took advantage of this fact to
quantitate the ability of Y. pestis to secrete effectors in the presence
of small molecules. The top overall scoring compounds were not
able to fully prevent the change in cell morphology at 50 mM
concentrations (Table 6). However, additional screens of
compounds showing activity in YopE secretion screen into
bacterial cell culture identified one compound, 3624, which was
able fully inhibit cytotoxicity effects to mammalian cells at 10 and
50 mM concentration. The compound was not identified in the
ATPase screen as its intrinsic fluorescence prevented use of the
Adapta assay. A small group of the compounds, including the
compound 4214, was only marginally effective in the cell
infection model.
Figure 7. Inhibition of Y. pestis KIM growth by selected small molecules. Attenuated Y. pestis KIM19 strain was grown in the presence of
100 mM inhibitor in HBI medium at 30uC as described under Materials and Methods. Control experiment was performed with 2% DMSO. Data were
normalized to the starting OD620=0.15 at 0 hr time. For a reference, the secretion of YopE protein (Fig. 6) was measured at t=3 hrs.
doi:10.1371/journal.pone.0019716.g007
Table 4. Secondary screen of YopE secretion inhibition by
selected small molecules.
Inhibitor Inhibition at 10 mM
ID %
DMSO+EGTA 068
7086 10660.5
7832 9760.4
7812 10360.2
The secretion of YopE was measured in the supernatants of bacterial cell culture
by ELISA using anti-YopE antibody as described under Materials and Methods.
The data were collected 1 hr post-induction with EGTA. Inhibitor
concentrations were 10 mM. Positive and negative controls correspond to the
results obtained for co-solvent (DMSO) without and with EGTA, respectively.
Error bars correspond to standard deviation of five measurements. Errors
correspond to standard deviation of five measurements.
doi:10.1371/journal.pone.0019716.t004
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Y. pestis is a human and animal pathogen responsible for the
epidemics of bubonic and pneumonic plagues as recently as the
twenty-first century [43]. In the U.S., plague is still endemic in the
western states in rodents, the main carrier of the pathogen [44].
Pneumonic plague is highly pathogenic in humans and antibiotics
must be administered within the first 24 hr post-infection. Due to
the natural emergence of antibiotic resistance in bacteria [45] and
the potential for a deliberate engineering of resistance in bacteria,
the search for non-antibiotic treatments of infectious diseases has
gained more attention in recent years [46]. The targeting of
virulence systems of pathogens, by rational drug design against a
given target, or by random screening of a library of compounds
inhibiting the transport of the virulence system, is a new strategy
[37,47].
The current strategies for targeting Yersinia pestis and other type
III secretion system-utilizing pathogens rely mostly on phenotypic
screens [3,9,48,49,50,51,52]. The strategy uses a library of random
compounds or a smaller set of molecules and the readout is a
blockage of secretion of a defined substrate into the host. The main
drawback is the non-specificity of the library targets which
necessitates secondary screens for elimination of general toxicity
compounds as opposed to those targeting specifically the virulence
system. Identification of the mechanism of action of the inhibitors is
not straightforward, either, and it usually requires a separate study
to differentiate between prevention of assembly of the injectisome
and blocking a specific function of a given protein. In addition, due
to the random nature of the library, there is a potential that the
targets may be mammalian proteins identified during subsequent
screening. In contrast, our approach uses a systems biology
approach to identify the potential target and validate it in an
animal model. The target is made by recombinant means and the
knowledge from structural biology and computational chemistry is
used to computationally select for molecules interfering with a
specific functional activity of the protein. The molecules are
computationally selected for binding to a defined region on the
target molecule and verified in vitro for blockage of the function and
in vivoto confirm theirability to blockthebacterial secretionprocess.
The strategy is potentially superior to the phenotypic screens as the
search is rational and directed against a very specific target. The
approach is typically faster, cheaper, more efficient and, as
demonstrated in our work, results in better inhibitors with less
experimental screening and potentially lower off-target hits.
We hypothesized that therapeutics should target bacterial
ATPases involved in the transport process. In Y. pestis, the only
T3SS ATPase is the YscN protein and therefore, this protein was
selected as a therapeutics target for plague. As expected, the target
was validated in a mouse model of bubonic plague. The
attenuation, over a million-fold (Table 1), of the DyscN mutant
pathogen was not caused by slower growth of the mutant (Fig. 2).
Due to the physical limitations of the animal model, higher
attenuation levels could not be determined. The results suggest
that the potency of future therapeutics directed against YscN may
approach levels observed for the currently-used antibiotics.
To help facilitate the development of therapeutics, the
optimized catalytic domain of YscN protein was purified from E.
coli as a fusion with MBP and characterized in detail. The purified
protein was catalytically active but also very prone to aggregation.
The homologous full-length YscN ATPase from Y. enterocolitica was
a mixture of different tertiary forms, from monomer to hexamer,
but started forming aggregates with a stoichiometry higher than six
when examined in the presence of a non-hydrolysable ATP analog
[35]. In the enteropathogenic E. coli, the homologous full-length
EscN ATPase eluted as a mixture of mostly monomeric and 12–
14-mer species in the presence of near-saturating substrate
concentrations [34]. Obviously, the T3SS ATPases oligomerize
easily and the optimized YscN catalytic domain from Y. pestis may
simply be more prone to aggregation than other proteins.
While some compounds exhibited average to poor values of
IC50, most of these were effective at blocking of YopE secretion at
100 mM concentration. Explanation of this conundrum may take
form of several possibilities. As noted above, we speculate that one
possibility is that these compounds hinder hexamer formation of
YscN and its consequent mechanical function, rather than inhibit
the catalytic turnover of ATP. Unlike the association of ADP to
YscN, which helps to regulate oligomerization, molecular
modeling of the hexamer suggests that the docked conformational
poses of the small molecules may interfere through steric
interactions with the correct orientation of adjoining protein
chains and their alignment in the multimeric assembly. Specifi-
cally, the N-terminal part of the YscN protein was predicted to be
essential for the hexamer formation. It is also plausible that the
truncated form of YscN used in the inhibition assay is not a true
functional mimic of the full chain and its activity in the oligomeric
state, thus yielding a weak correlation between the ATPase
inhibition and YopE secretion data. A final possibility is that there
may be additional binding sites on YscN that can accommodate
the small molecules and/or perhaps there are off-target proteins
with sufficient sequence similarity with YscN (e.g., type III
Table 5. Cytoxicity of selected small molecules against
human HeLa cells.
Inhibitor Inhibition at 100 mM
ID %
Methanol 10061
DMSO 0620
7086 26611
7832 068
7812 0618
The top overall scoring inhibitors were incubated at 100 mM concentration with
HeLa cells as described under Materials and Methods. The toxicity was
measured by the ability of cells to metabolize calcein-AM using LIVE/DEAD kit
(Invitrogen). Methanol and 2% DMSO were used as positive and negative
controls, respectively. Error bars correspond to S.E.M from triplicate
measurements.
doi:10.1371/journal.pone.0019716.t005
Table 6. Inhibition of HeLa cell toxicity by attenuated Y. pestis
in the presence of selected small molecule inhibitors.
Inhibitor Inhibition at 50 mM Inhibition at 10 mM
ID % %
7086 20 0
7832 30 0
7812 0 0
The HeLa cells were incubated with attenuated Y. pestis KIM19 strain in the
presence of small molecules in DMEM medium supplemented with 10% FBS as
described under Materials and Methods. Cell toxicity was scored by calculating
the percentage of rounded versus the squamous cells under a microscope. Only
data for molecules showing 10% or more inhibition of cell rounding at 50 mM
inhibitor concentration are shown.
doi:10.1371/journal.pone.0019716.t006
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inhibitors and disrupt the transport of virulence factors. Nonethe-
less, even though our goal of in silico screening was for enzymatic
inhibitors, we discovered a set of molecules that block secretion
through perhaps an alternative mode of action. The exact details
at atomic-level resolution of how these molecules fully work
remain to be determined from X-ray crystallographic studies and
further protein-binding assays.
The differences between the in vivo and in vitro data were
investigated in more detail. The most likely explanation, inhibition
of bacterial growth, was proven not to be the cause for any of the
selected compounds (Fig. 7) except for the compound 7086. An
alternative explanation, bioavailability, was investigated indirectly
by screening the YopE secretion inhibition at 10 mM concentration
of inhibitors (Table 4). While for many of the molecules there was
still not a clear correlation between the in vivo and in vitro data, three
of the top ten scoring inhibitors from the activity assay were
confirmed in the in vivo assay: compounds 7812, 7832 and 7086.
Compound 7086 may additionally exert its effect through a slight
inhibition of bacterial growth (3 hr time point in Fig. 7). The
compounds were also non-toxic (7812 and 7832) or only slightly
toxic (7086) to the mammalian cells at ten-fold higher concentra-
tions (Table 5), suggesting that the molecules have a low potential to
target human enzymes, ATPases in particular. A full evaluation of
the therapeutic potential will require a separate study in the future.
However, the low toxicity against human cells shown in the current
work is very important for future therapeutics development.
The final test of potential therapeutic applications of the small
molecules was performed in the cell culture model of infection.
The best overall scoring molecules capable of inhibiting both
YopE secretion and ATPases activity (7086, 7812 and 7832) were
only moderately effective in preventing the morphological changes
in infected HeLa cells (Table 6). However, the best inhibitor in the
cell culture model, compound 3624, was relatively potent in the
second YopE secretion assays (60% at 10 mM). Since the
compound was relatively non-toxic to HeLa cells (20% at
100 mM), the molecule could be optimized in future to increase
potency and lower toxicity.
The identified compounds are novel and have not been tested in
similar studies [3,9,48]. However, a search of chemical databases
identified many analogs of the top scoring compounds from
different assays performed in the current work (Table S1).
Elucidation of the mechanism of action of the top scoring
compounds and their full therapeutic potential is beyond the scope
of the current work.
Our results show that the strategy to block virulence of human
pathogens can be based on small molecules targeting motor
proteins of bacterial secretory systems. The proteins are easy to
identify by bioinformatics methods and shown to be essential for
virulence in many systems. It is possible that the strategy presented
in the current work could be used to develop novel therapeutics for
many other T3SS-encoding pathogens, including Salmonella
typhimurium, EPEC/EHEC, Shigella flexneri, Campylobacter jejuni,
Pseudomonas aeruginosa, Burkholderia mallei and many others.
Materials and Methods
Bacterial strains and media
The following reagent was obtained through the NIH
Biodefense and Emerging Infections Research Resources Repos-
itory, NIAID, NIH: Yersinia pestis, Strain KIM Derivative 19 (D19),
NR-4681, Yersinia pestis, Strain KIM Derivative 2 (D2), NR-4682.
For routine growth of the fully virulent pathogen, Y. pestis was
maintained on sheep blood agar plates or in heart infusion broth
(HIB) with 0.2% xylose. For mutant construction, Y. pestis was
incubated at 28uC on Luria-Bertoni (LB) Lennox plates supple-
mented with ampicillin at 50 mg/mL or 5% sucrose. For
determining colony-forming units (CFU), the bacteria were
incubated on sheep blood agar plates (SBAP). The Y. pestis
KIM19 strain was propagated on sheep blood agar plates and
small (3–10 ml) bacterial cultures for YopE secretion controls were
made in HIB supplemented with 0.2% xylose.
Chemicals and reagents
Most of the common chemicals were purchased either from
Sigma Aldrich or Fisher Scientific. Protease inhibitors cocktails
without EDTA were purchased from Roche Diagnostics. Small
molecule compounds identified in the computational screen of
ZINC database were purchased either from Life Chemicals or
from Enamine as dry powders. Stock solutions of the compounds
in dimethylsulfoxide (DMSO) and/or dimethylformamide (DMF)
were made in-house. The stocks were stored at 220uC in amber
glass vials. Serial dilutions of the stocks with DMSO were made
from the thawed stocks when required and stored at 220uCi n
amber glass vials as well. YopE antibody and the positive control
antigen were purchased from Santa Cruz Biotechnology and the
mouse anti-goat antibody HRP conjugate was purchased from
Thermo Scientific.
Suicide vector construction
The yscN gene fragment, basepairs (bp) 1–300 and 1020–1317,
together with about 1 kb extensions on both 39 and 59 ends, was
amplified by overlap extension PCR [53] using genomic DNA
from Y. pestis CO92 as a template. The full construct was cloned
into the suicide vector pCVD442 [54] and transformed into a pir
+
strain TransforMax EC100D pir
+ electrocompetent cells (Epicen-
tre Biotechnologies, Inc.) by electroporation. The yscN gene
deletion in the construct, bp.301–1019, and inclusion of the
overlapping 1 kb fragments on each side of the yscN gene, was
verified by PCR and DNA agarose gel electrophoresis.
Gene deletion in Y. pestis CO92
To inactivate the yscN gene from the pCD1 plasmid of CO92
strain of Y. pestis, the plasmid containing the mutant yscN (DyscN
long) was introduced by electroporation [55] using a (BioRad
Laboratories) MicroPulser Electroporator with 0.1 cm cuvettes.
Cointegrates were selected on LB agar plates in the presence of
50 mg/mL of ampicillin. The cointegrate strains were grown
overnight in HIB and plated on LB agar plates containing sucrose
to select for allelic exchange recombinants, as pCVD422 contains
the sacB gene [56]. Those colonies which grew in the presence of
sucrose were screened by PCR to demonstrate the deletion of the
yscN gene. To confirm that the virulence plasmid was still present
in the DyscN CO92 strain and not lost during in vitro growth, a
primer pair set directed against the V-antigen was utilized for PCR
amplification to demonstrate its presence (data not shown).
Likewise, the DyscN mutant strain was screened on Congo Red
[57] agar plates to confirm the pgm locus was intact.
Yersinia pestis DyscN growth curve determination. To
determine the growth profile of the DyscN mutant, overnight
cultures of the wt and mutant strains in HIB supplemented with
0.2% xylose were inoculated into fresh medium at the cell density
corresponding to OD620 of approximately 0.05 and grown at 28uC
at 150 rpm. The growth of bacteria was then monitored by
measuring OD620 for up to 20 hrs.
The Y. pestis wild-type and DyscN strains were prepared for
mouse inoculations as previously described [58], except that the
bacteria were suspended in 10 mM potassium phosphate buffer
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Swiss-Webster mice were inoculated via the subcutaneous route
with 0.2 mL aliquots of the DyscN Y. pestis mutant at the following
doses: 0, 10
2,1 0
3,1 0
4,1 0
5,1 0
6 and 10
7 CFU. The intermediate
data for survival after 21 days post-inoculation are shown in
Table 1 for the purpose of the current work. The data are a part of
a separate experiment which was performed over 65 days in total
and the results will be published in a separate manuscript. After 65
days, the survivors were humanely euthanized.
For control experiments, the non-inoculated animals were
challenged with 180 CFU (approximately 90 LD50) of the wild-
type Y. pestis CO92 strain via the s. c. route. The animals were
observed for 21 days after which survivors were humanely
euthanized.
Statistics
To determine differences between the immunized groups and
control group, the following determinations were made. Survival
rates were compared by Fisher exact tests with stepdown
Bonferroni adjustments. The above analyses were conducted
using SAS Version 8.2 (SAS Institute Inc., SAS OnlineDoc,
Version 8, Cary, NC 2000).
YscN gene cloning
The synthetic gene, corresponding to the amino acid (a.a.) 95–
419 of the Y. pestis YscN protein (Figure S1) was optimized for E. coli
expression in silico and assembled using standard synthetic chemistry
methods (GenScript). The gene was cloned into pMAL-c4E
expression vector (New England Biolabs) between EcoRI and
HindIII sites and the final construct was verified by DNA
sequencing. The final construct coded for a cleavable (enterokinase)
N-terminal fusion with a maltose binding protein (MBP) and a non-
cleavable C-terminal 106His affinity tag. The separation of tags
was designed to minimize protein degradation during purification.
For protein expression, the clones were transformed into BL21
(DE3) expression strain (EMD), verified by SDS-PAGE to express
the desired protein, and stored as glycerol stocks at 280uC.
The bsaS gene (B. mallei ATCC 233344) coding for BsaS protein
fragment corresponding to amino acids (a.a.) 18–433 (Figure S2)
was optimized for E. coli expression in silico and assembled
(GeneScript) as described for the Y. pestis yscN gene. The final
construct was cloned in pMAL-p5E vector (NEBiolabs) between
KpnI and BamHI sites. The corresponding ORF of bsaS gene had
all Cys residues replaced by Ser. The plasmid construct was
transformed into NEB Express (NEBiolabs) E. coli strain for
protein expression.
Protein expression and purification
To express the YscN protein fragment, stock of the verified clone
was streaked onto a fresh LB+ampicillin (50 mg/mL) agar plate and
grown overnight at 37uC. A single colony was selected to inoculate
3m Lo fL B +ampicillin (50 mg/mL) medium. The cells were grown
overnight at 37uC in an incubator with shaking at 200 rpm. The
next day, the cell culture was diluted 1:10 into a fresh medium and
incubated at 37uC with shaking for 2 hr. The culture propagation
was continued until the final dilution, typically 2–4 L of Overnight
Express Instant TB medium (EMD) supplemented with antibiotic
(50 mg/mL ampicillin), was reached. The culture was incubated for
an additional time until the cell density reached OD600=0.4–0.6.
At that time, the culture was chilled to 22uC in the shaker and a
solution of isopropyl-b-D-thiogalactopyranoside (IPTG) was added
to a final concentration of 0.3 mM. The culture resumed shaking
for an additional 16–20 hr. Cells were harvested by centrifugation
was and stored at 220uC (short term) or 280uC (long term) before
extraction of proteins.
To purify proteins, the cell paste was thawed at room
temperature (25uC) for about 30–60 min, resuspended in chilled
200–400 mL of protein binding buffer (10 mM Tris, pH=8.0,
150 mM NaCl, 10% glycerol, 40 mM imidazole) supplemented
with Complete EDTA-free (Roche Diagnostics) protease inhibitor
cocktail. The bacterial paste was homogenized using the M-110-P
20 Microfluidizer (Microfluidics), the debris removed by centrifu-
gation, the supernatant filtered through a sterile 0.45 mm filter and
purified on AKTAExpress Single (GE Healthcare) automated
protein purification chromatography system using a three-step
protocol: Ni-agarose (HisTrap Crude FF 5 mL), gel filtration
(HiLoad Superdex 200 26/60) and amylose resin (MBP Trap HP
5 ml) according to the standard methods. The protein fractions
were buffer exchanged into 10 mM Tris, pH 7.6, 150 mM NaCl,
10% glycerol and concentrated to 0.6–0.9 mg/ml using the
Amicon Ultra-15 concentrators (Millipore). Protein concentration
was determined with an RC DC Protein Assay kit II (Bio-Rad
Laboratories) with bovine serum albumin (BSA) as a standard.
The concentrated protein was distributed into aliquots and stored
at 220uC for experiments. Typically, 1–2 mg of purified YscN
protein was obtained from 1 L of bacterial cell culture.
The procedures for purification of BsaS protein were identical
to the procedures described for the YscN protein with one
exception: the bacterial culture was scaled up to 10 L to
compensate for the low expression levels of the recombinant
MBP-BsaS protein fusion.
Comparative protein modeling of YscN
Because of the lack of an experimental structure of YscN
ATPase from either X-ray crystallographic or NMR determina-
tion, a comparative protein model was developed at atomic-level
resolution. Protein structure prediction of YscN was carried out by
using the protein homology/analogy recognition engine (Phyre)
server [59]. Twenty hits were culled from profile-profile threading
of the YscN sequence through a database of known protein folds
and the top-ranked match yielded the protein PDB ID: 2dpy,
which is an X-ray crystal structure of a flagellum-specific ATP
synthase in the ADP-bound form. From the Phyre alignment, the
computed pairwise sequence identity between YscN and 2dpy was
45%, thus enabling an accurate three-dimensional comparative
model to be constructed for YscN. Hydrogen atoms were added to
the comparative model by the CHARMM package [60].
Computational screening of ZINC database
The ZINC chemical database (version 8) [36] was searched by
virtual screening and the database contained approximately 5
million commercially available compounds with predicted drug-
like chemical properties. Small-molecule docking of the Zinc
library to the YscN protein model was achieved by using the
DOVIS large-scale virtual screening pipeline [61]. The docking
engine implemented in DOVIS is AutoDock 4.0 [62] and for the
application presented here, we modeled the YscN protein as a
rigid-body molecule while the ligands were allowed to be flexible
around torsional angles. The energy grid center was defined as the
geometrical center of the YscN ADP-binding site (2dpy reference
frame) at (x=8.0, y=4.4, z=41.0) with a volume of
30620620 A ˚ 3 at a grid-resolution spacing of 0.375 A ˚. AutoDock
parameters were set as follows: 10 genetic algorithm runs were
executed, each with population size of 150, one million energy
evaluations, and a maximum of 27,000 generations per genetic
algorithm run. Three clusters were saved per ligand with a root-
mean-square-deviation of at least 1.5 A ˚. The default AutoDock
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conformational poses for each ligand and to down-select the top
20,000 compounds from the sampled 5 million.
For each of the top 20,000 compounds ranked by AutoDock 4.0
score, the top three docked complexes were minimized with 200
steps of the adopted basis Newton-Raphson method using
CHARMM [60] with the MMFF force field [63] and a
distance-dependent dielectric solvent term (e=4). OpenBabel
software was used to interconvert between SDF, MOL2, and PDB
format as required. The minimized complexes were re-scored with
LigScore2 (Accelrys, Inc.) [64]. The top 50 compounds ranked by
LigScore2 that were available from the commercial vendors
Enamine and Life Chemicals were selected and purchased.
Enzyme activity assays
Phosphate release assay. The EnzCheck Phosphatase
Assay kit (Invitrogen, CA) was used in the initial screening for
YscN ATPase activity. The determination of released phosphate
was performed with the EnzCheck Phosphatase Assay kit
(Invitrogen, CA) according to manufacturer guidelines. Data
analysis and graphing were performed with KaleidaGraph
(Synergy Software, PA) software.
ADP release assay. The Adapta Universal Kinase kit
(Invitrogen, CA) was used to screen for inhibition of YscN and
BsaS ATPase activities by the small-molecule inhibitors derived
from computational screen. Due to the relatively low activity of the
recombinant enzymes, the assay was modified for low
concentrations of ATP in the reaction mixture as described below.
ADP release assay calibration. To maximize the ability of
the assay to detect ATPase inhibitors at 10 mM ATP working
concentration, the amount of tracer used in the assay was equal to
the amount recommended by the manufacturer for 1 mM ATP
concentration. The samples were analyzed using the Synergy 4
(Biotek, Inc.) microplate plate reader according to the
manufacturer’s instructions. The optimal concentration of the
protein selected for inhibitor screening corresponded to the
amount required to elicit an approximately 80% change (EC80)
in the assay signal. The EC80 determination was performed for
each lot of the recombinant enzyme.
Preliminary molecule screening for ATPase activity
inhibition. The potential inhibitors were resuspended in a
mixture of DMSO and DMF to a standard concentration of
50 mg/mL. Due to the solubility problems of the small molecules,
only 37 out of the total of 50 compounds could be used for making
stock solutions at 50 mg/ml. The insoluble compounds were not
used for further testing. For screening, the inhibitors were diluted
to 5 mg/mL in DMSO and the ADP release was analyzed using
the Adapta Universal Kinase kit (Invitrogen, CA) as described.
Determination of IC50 values. Compounds demonstrating
near-complete inhibition of ADP release at 100 mM concentration
were serially diluted 1:10 in DMSO and assayed for inhibition at
100, 10, 1, and 0.1 mM final concentrations. Since all of the
compounds were non-inhibitory below 1 mM final concentration,
each inhibitor was tested at 0.7–100 mM final concentration range.
The data were imported into KaleidaGraph (Synergy Software,
PA) software for analysis. The IC50 values were determined from
the sigmoid-fitting model supplied with the software.
Screening of small molecules for inhibition of YopE
secretion in a bacterial cell culture. The secretion of YopE
protein was performed in a method similar to one previously
described [65]. An overnight culture of Y. pestis KIM19 was grown
from a single colony in 25 mL of HIB medium supplemented with
2.5 mM CaCl2 and 0.2% xylose at 26uC. The culture was then
diluted to an OD600 of approximately 0.2 in fresh medium and
split into 5 mL samples. Various YscN inhibitors were added to
the separate culture tubes, each at concentration of 100 mM. A
negative control was DMSO without inhibitor. The cultures were
then allowed to grow at 26uC for 1 hr and the temperature was
shifted to 37uC for an additional hour. After that time, 500 ml
samples were taken to provide a baseline measurement of YopE
secretion and EGTA was added to a concentration of 10 mM in
all but the negative control. The cultures were returned to the
incubator for additional 1 hr incubation at 37uC. At the end of the
incubation, another set of 500 mL samples were removed from the
cultures, centrifuged immediately at 16,000 rpm for 5 min. and
the supernatants were passed through 0.22 mM filters. The
detection of secreted YopE was performed by ELISA.
Determination of secreted YopE in cleared bacterial
culture supernatants by ELISA. Samples from the YopE
secretion assay were analyzed either undiluted or at a 1:10 dilution
in water. The primary antibody was goat anti-YopE (1:500
dilution) and the secondary was mouse anti-goat HRP conjugate
(1:3000 dilution). The visualization was performed with the ABTS
peroxidase solution by reading absorbance at 405 nm on the
Synergy 4 (BioTek, Inc.) microplate reader. Data manipulation
and plotting were performed with KaleidaGraph software
(Synergy Software).
Inhibition of mammalian cell culture toxicity by selected
small molecules
HeLa cell preparation. Two days prior to infection with
attenuated Y. pestis strain, 200 mLo f3 . 5 610‘4 cells/mL of HeLa cells
in DMEM medium containing 10% FBS were placed into a 96 well
plate. The plates were incubated for 2 days at 37uCw i t h5 %C O 2 .
Bacterial cell preparation. Two to three days prior to the
infection of mammalian cells, a blood agar plate was streaked from
a frozen stock of Y.pestis KIM19, containing the pCD1 plasmid,
and KIM2, lacking the pCD1 plasmid, and incubated at 26uC.
The day before infection, 3 mL of HIB broth was inoculated with
a single colony from the blood agar plate and incubated at 26uC
while shaking at 300 rpm. The following morning, a 5 mL aliquot
of the Y. pestis culture was used to inoculate 500 mL of DMEM
medium supplemented with 3% FBS and the inhibitor at a
concentration of 50 or 10 mM dissolved in DMSO. The final
concentration of DMSO in the culture was 1%. These cultures
were incubated for 1 hour at 26uC while shaking at 200 rpm.
Infection of mammalian cells. After a one hour of
incubation of HeLa cells with Y. pestis, the plates containing the
HeLa cells were removed from the incubator and the media was
removed by aspiration. A 150 mL aliquot of the various cultures
containing the inhibitors or DMSO control were placed into
duplicate wells and the plates were incubated for 3 hours at 37uC
with 5% CO2. Following the incubation, the plates were removed
from the incubator and analyzed by optical microscopy. The
number of rounded and squamous cells was counted manually and
the percent of squamous cells was compared to the controls.
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